24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Publication dates

Leukemia Industry, March 2015 Market Reports from Top Publishers

You might be interested in: flow cytometry, hematology, therapeutics, nucleic acid testing, medical equipment, cancer, melanoma, pap smear, lymphoma, stem cell, biomarker, breast cancer, cancer therapeutics, colorectal cancer, hospital.


 
1-10 of about 200 reports for Leukemia

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  • $ 2 000
  • Industry report
  • February 2015
  • by Delve Insight

DelveInsight's, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about ...

Chronic Lymphocytic Leukemia (CLL)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Chronic Lymphocytic Leukemia (CLL)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  • $ 2 000
  • Industry report
  • February 2015
  • by Delve Insight

DelveInsight's, “Chronic Lymphocytic Leukemia (CLL)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and ...

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  • $ 2 000
  • Industry report
  • February 2015
  • by Delve Insight

DelveInsight's, “Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase ...

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  • $ 2 000
  • Industry report
  • February 2015
  • by Delve Insight

DelveInsight's, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase ...

B-Cell Chronic Lymphocytic Leukemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

B-Cell Chronic Lymphocytic Leukemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  • $ 2 000
  • Industry report
  • February 2015
  • by Delve Insight

DelveInsight's, “B-Cell Chronic Lymphocytic Leukemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and ...

Meningeal Leukemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Meningeal Leukemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  • $ 2 000
  • Industry report
  • February 2015
  • by Delve Insight

DelveInsight's, “Meningeal Leukemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs ...

T-Cell Leukemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

T-Cell Leukemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  • $ 2 000
  • Industry report
  • February 2015
  • by Delve Insight

DelveInsight's, “T-Cell Leukemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across ...

Leukemia Drug Pathway Analyzer 2015

Leukemia Drug Pathway Analyzer 2015

  • $ 2 249
  • Industry report
  • January 2015
  • by Bioseeker

Extra value: One year of free online updates included with this product There are today at least 435 targeted molecular therapies known to affect more than 246 specific intracellular signaling pathways ...

EpiZyme, Inc. (EPZM) - Financial and Strategic SWOT Analysis Review

EpiZyme, Inc. (EPZM) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • January 2015
  • by Global Data

Summary EpiZyme, Inc. (Epizyme) is a biopharmaceutical company. The company discovers and develops molecular targeted drugs for the treatment of oncology and metabolic diseases. Epizyme's products include ...

Kancera AB (KAN) - Financial and Strategic SWOT Analysis Review

Kancera AB (KAN) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • January 2015
  • by Global Data

Summary Kancera AB (Kancera) is pharmaceutical company which develops the basis for new therapeutics. It starts with new treatment concepts and ends with the sale of drug candidate to pharmaceutical companies. ...

About 1 600 reports for Leukemia

Download Unlimited Documents from Trusted Public Sources

Pathology Description in the US

  • April 2014
    28 pages
  • Cancer  

  • United States  

    North America  

View report >

17 Companies for Leukemia

Read our Company Profiles

Celgene Corp.

United States

GlaxoSmithKline P.L.C.

United States

Bristol-Myers Squibb Co.

United States

GlaxoSmithKline PLC

United Kingdom

Novartis Inc.

Switzerland

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.